Pharma Equity Group A/S (CPH:PEG)

Market Cap	139.33M
Revenue (ttm)	n/a
Net Income (ttm)	-21.02M
Shares Out	1.23B
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,212
Average Volume	1,292,597
Open	0.0980
Previous Close	0.1135
Day's Range	0.0980 - 0.1135
52-Week Range	0.0706 - 0.1895
Beta	0.83
RSI	63.54
Earnings Date	Nov 14, 2025

About Pharma Equity Group

Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which current therapy is lacking or in need of improvement. Its products under development that are in Phase II clinical trials include RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment of Ulcus Cruris chronic skin ulcers; RNX-041 for the treatment of inflammatory bowel diseases, such as chrons and pouch...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Country: Denmark
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: PEG